Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling

Journal of Medicinal Chemistry

Volumn 49, Issue 15, 2006, Pages 4470-4476

  Hobrath, Judith Varady ^a   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; LIGAND;

ARTICLE; BINDING SITE; CALCULATION; COCAINE DEPENDENCE; DRUG PROTEIN BINDING; DRUG STRUCTURE; LIGAND BINDING; PARKINSON DISEASE; PREDICTION; RECEPTOR AFFINITY; SCHIZOPHRENIA; SCORING SYSTEM; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS;

BINDING SITES; COMPUTER SIMULATION; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTAGENESIS, SITE-DIRECTED; MUTATION; RECEPTORS, DOPAMINE D3; SEQUENCE HOMOLOGY, AMINO ACID; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES;

EID: 33746740424     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0501634     Document Type: Article

References (75)

1. 3) as a target for neuroleptics. Nature 1990, 347, 146-151.
2. 3 receptor mRNA and binding sites in human brain. Brain Res. Mol. Brain Res. 1993, 18, 187-192.
3. 2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11271-5.
4. 2 receptor mRNA. Brain Res. 1991, 564, 203-219.
5. Fibiger, H. C.; Phillips, A. G. Dopamine systems and reward. Ann. N. Y. Acad. Sci. 1988, 537, 206-215.
6. McBride, W. J.; Murphy, J. M.; Ikemoto, S. Localization of brain reinforcement mechanisms: intracranial self-stimulation and intracranial place-conditioning studies. Behav. Brain Res. 1999, 101, 129-152.
7. Emilien, G.; Maloteaux, J.-M.; Geurts, M.; Hoogenberg, K.; Cragg, S. Dopamine receptors - physiological understanding to therapeutic intervention potential. Pharmacol. Ther. 1999, 84, 133-156.
8. Schwartz, J.-C.; Diaz, J.; Pilon, C.; Sokoloff, P. Possible implications for the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res. Rev. 2000, 31, 277-287.
9. Strange, P. G. Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 2001, 53, 119-133.
10. 3 dopamine receptor, behavioral sensitization and psychosis. Neurosci. Biobehav. Rev. 2001, 25, 427-443.
11. Carroll, F. I.; Howell, L. L.; Kuhar, M. J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 1999, 42, 2721-2731.
12. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49, 231-252.
13. Zhang, J.; Xu, M. Toward a molecular understanding of psychostimulant actions using genetically engineered dopamine receptor knockout mice as model systems. J. Addict. Dis. 2001, 20, 7-18.
14. Shapiro, R. M. Regional neuropathology in schizophrenia: where are we? Where are we going? Schizophr. Res. 1993, 10, 187-239.
15. 3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1997, 54, 225-232.
16. 3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Ann. N. Y. Acad. Sci. 1999, 877, 595-613.
17. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 1998, 10, 2565-2573.
18. 3 dopamine receptors. Science 1993, 260, 1814-6.
19. 3 receptor agonist. Nature 1999, 400, 371-375.
20. McBride, W. J.; Murphy, J. M.; Ikemoto, S. Localization of brain reinforcement mechanisms: intracranial self-stimulation and intracranial place-conditioning studies. Behav. Brain Res. 1999, 101, 129-152.
21. 3 receptor ligands with antagonist properties. ChemBioChem. 2002, 3, 946-961.
22. Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic Agents, J. Med. Chem. 2005, 48, 3663-3679.
23. 3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J. Med. Chem. 2003, 46, 4377-4392.
24. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289, 739-745.
25. Baldwin, J. M.; Schertler, G. F. X.; Unger, V. M. An Alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 1997, 272, 144-164.
26. Efremov, R. G.; Nolde, D. E.; Vergoten, G.; Arseniev, A. S. A solvent model for simulations of peptides in bilayers. II. Membrane-spanning α-helices. Biophys. J. 1999, 76, 2460-2471.
27. Heller, H.; Schaefer, M.; Schulten, K. Molecular dynamics simulation of a bilayer of 200 lipids in the gel and in the liquid-crystal phases. J. Phys. Chem. 1993, 97, 8343-8360.
28. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
29. Ballesteros, J. A.; Shi, L.; Javitch, J. A. Structural mimicry in G protein-coupled receptors: implications of the high-resolution of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60, 1-19.
30. Shi, L.; Javitch, J. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
31. 2 receptor exposed in the binding-site crevice. Biochemistry 1995, 34, 16433-39.
32. 2 receptor by the substituted-cysteine accessibility method. Neuron 1995, 14, 825-831.
33. 2 receptor: Accessibility in the binding site crevice and position in the transmembrane bundle. Biochemistry 2001, 40, 12339-12348.
34. 2 receptor is accessible in the binding-site crevice. Biochemistry 1998, 37, 998-1006.
35. 2 receptor: contributions of the second membrane-spanning segment. Biochemistry 1999, 38, 7961-68.
36. 2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 2000, 39, 12190-99.
37. 2 receptor accessible in the binding-site crevice. Biochemistry 1996, 35, 11278-85.
38. 2 dopamine receptor is exposed in the binding-site crevice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10355-59.
39. 2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice. Mol Pharmacol. 1996, 49, 692-698.
40. Quanta, a molecular modeling system, supplied by Accelrys., San Diego, CA.
41. Insight II, a molecular modeling system, supplied by Accelrys, San Diego, CA.
42. 3 dopamine receptors. Neuropsychopharmacology 1995, 12, 335-345.
43. 2 receptor. Eur. J. Pharmacol. 1998, 346, 299-307.
44. Vanhauwe, J. F.; Fraeyman, N.; Francken, B. J.; Luyten, W. H.; Leysen, J. E. Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 1999, 290, 908-916.
45. 3 receptor measured by guanosine 5′-gamma- thiotriphosphate-35S-binding. J. Pharmacol. Exp. Ther. 1998, 285, 119-126.
46. 2, a molecular modeling system, supplied by Accelrys Inc., San Diego, CA.
47. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
48. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Docking of flexible ligands: Applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
49. Kalani M. Y. S.; Vaidehi, N.; Hall, S. E.; Trabanino, R. J.; Freddolino, P. L.; Kalani, M. A.; Floriano, W. B.; Kam, V. W. T.; Goddard, W. A., III The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3815-20.
50. 3 dopamine receptors. J. Neurochem. 1999, 72, 2621-2624.
51. 3 receptors. Mol. Pharmacol. 1994, 46, 299-312.
52. 1a receptor ligands to explore the three-dimensional structure of the receptor. Mol. Pharmacol. 2002, 62, 15-21.
53. Carlson, H. A.; McCammon, J. A. Accommodating protein flexibility in computational drug design. Mol. Pharmacol. 2000, 57, 213-218.
54. Knegtel, R. M. A.; Kuntz, I. D.; Oshiro, C. M. Molecular docking to ensembles of protein structures. J. Mol. Biol. 1997, 266, 424-440.
55. 2 receptor selectivity is determined by a divergent aromatic microdomain contained within the second, third and seventh membrane-spanning segments. Mol. Pharmacol. 1999, 56, 1116-1126.
56. 2 receptor. Eur. J. Pharmacol. 1992, 227, 205-214.
57. 3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents. Br. J. Pharmacol. 1998, 125, 705-710.
58. 2 dopamine receptor on ligand binding. J. Neurochem. 2000, 74, 358-366.
59. 2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol. Pharmacol. 1998, 54, 435-444.
60. Cox, B. A.; Henningsen, R. A.; Spanoyannis, A.; Neve, R. L.; Neve, K. A. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors. J. Neurochem. 1992, 59, 627-635.
61. 2 dopamine receptors. J. Med. Chem. 2000, 43, 3005-19.
62. 2 dopamine receptor are important for binding and signal transduction. J. Neurochem. 1995, 65, 2105-15.
63. Cotte, N.; Balestre, M. N.; Aumelas, A.; Mahe, E.; Phalipou, S.; Morin, D.; Hibert, M.; Manning, M.; Durroux, T.; Barberis, C.; Mouillac, B. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs antagonist ligand binding. Eur. J. Biochem. 2000, 267, 4253-63.
64. Granas, C.; Nordvall, G.; Larhammar, D. Mutagenesis of the human 5-HT1B receptor: differences from the closely related 5-HT1A receptor and the role of residue F331 in signal transduction. J. Recept. Signal. Transduct. Res. 1998, 18, 225-241.
65. Wieland, K.; Zuurmond, H. M.; Krasel, C.; Ijzerman, A. P., Lohse, M. J. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the β2-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 9276-81.
66. 2 dopamine receptors: mutation of a histidine residue specifically affects the binding of a subgroup of substituted benzamide drugs. J. Neurochem. 1994, 62, 1664-1669.
67. 3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system J. Recept. Signal Transduct. Res. 1998, 18, 133-150.
68. 1 transmembrane chimeras. Mol. Pharmacol. 1998, 54, 379-388.
69. 2 dopamine receptor. Biochem. Soc. Trans. 1994, 22, 144S.
70. Sonesson, C.; Lin, C.-H.; Hansson, L.; Waters, N.; Svensson, K.; Carlsson, A.; Smith, M. W.; Wikstrom, H. Substituted (S)-Phenyl-piperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J. Med. Chem. 1994, 37, 2735-53.
71. 2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 1995, 275, 885-898.
72. 3 dopamine receptor. J. Pharmacol. Exp. Ther. 1994, 268, 417-426.
73. Vanhauwe, J. F.; Josson, K.; Luyten, W. H.; Driessen, A. J.; Leysen, J. E. G-protein sensitivity of ligand binding to human dopamine D(2) and D(3) receptors expressed in Escherichia coli: clues for a constrained D(3) receptor structure. J. Pharmacol. Exp. Ther. 2000, 295, 274-283.
74. Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; Cooke, L. W.; Whetzel, S. Z.; MacKenzie, R. G.; Shih, Y. Y.; van Leeuwen, D. H.; DeMattos, S. B.; Georgic, L. M. CI-1007, a dopamine partial agonist and potential antipsychotic agent. 1. Neurochemical effects. J. Pharmacol. Exp. Ther. 1995, 274, 898-911.
75. 3 receptors. Neuropharmacology 1995, 34, 1693-1696.